In:
PLOS Medicine, Public Library of Science (PLoS), Vol. 18, No. 2 ( 2021-2-3), p. e1003495-
Kurzfassung:
MB66 film is a multipurpose prevention technology (MPT) product with monoclonal antibodies (mAbs) against HIV-1 (VRC01-N) and HSV-1 and 2 (HSV8-N). The mAbs were produced by transient expression in Nicotiana benthamiana (N). We conducted a Phase I clinical trial to assess the safety, pharmacokinetics (PK), and ex vivo efficacy of single and repeated doses of MB66 when used intravaginally. Methods and findings The clinical trial enrolled healthy reproductive-aged, sexually abstinent women. In Segment A, 9 women received a single MB66 film which was inserted into the vaginal posterior fornix by a clinician. In Segment B, 29 women were randomly assigned to MB66 (Active) or Placebo film groups and were instructed to insert 1 film vaginally for 7 consecutive days. Visits and clinical sampling occurred predose and at various time points after single and repeated film doses. The primary endpoint was number of adverse events (AEs) Grade 2 or higher related to product use. Secondary endpoints included film dissolution rate, Nugent score (a Gram stain scoring system to diagnose bacterial vaginosis), vaginal pH, post-use survey results, cytokine concentrations in cervicovaginal lavage (CVL) specimens (assessed by Luminex assay), mAb concentrations in vaginal fluid collected from 4 sites (assessed by ELISA), and HIV and HSV neutralization activity of CVL samples ex vivo (assessed by TZM-bl and plaque reduction assay, respectively). The product was generally safe and well tolerated, with no serious AEs recorded in either segment. The AEs in this study were primarily genitourinary in nature with the most commonly reported AE being asymptomatic microscopic hematuria. There were no differences in vaginal pH or Nugent scores or significant increases in levels of proinflammatory cytokines for up to 7 days after film insertion in either segment or between Active and Placebo groups. Acceptability and willingness to use the product were judged to be high by post-use surveys. Concentrations of VRC01-N and HSV8-N in vaginal secretions were assessed over time to generate pharmacokinetic curves. Antibody levels peaked 1 hour postdosing with Active film (median: 35 μg/mL) and remained significantly elevated at 24 hours post first and seventh film (median: 1.8 μg/mL). Correcting for sample dilution (1:20), VRC01-N concentrations ranged from 36 to 700 μg/mL at the 24-hour time point, greater than 100-fold the IC 50 for VRC01 (0.32 μg/mL); HSV8-N concentrations ranged from 80 to 601 μg/mL, well above the IC 50 of 0.1 μg/m. CVL samples collected 24 hours after MB66 insertion significantly neutralized both HIV-1 and HSV-2 ex vivo. Study limitations include the small size of the study cohort, and the fact that no samples were collected between 24 hours and 7 days for pharmacokinetic evaluation. Conclusions Single and repeated intravaginal applications of MB66 film were safe, well tolerated, and acceptable. Concentrations and ex vivo bioactivity of both mAbs in vaginal secretions were significantly elevated and thus could provide protection for at least 24 hours postdose. However, further research is needed to evaluate the efficacy of MB66 film in women at risk for HIV and HSV infection. Additional antibodies could be added to this platform to provide protection against other sexually transmitted infections (STIs) and contraception. Trial registration ClinicalTrials.gov NCT02579083 .
Materialart:
Online-Ressource
ISSN:
1549-1676
DOI:
10.1371/journal.pmed.1003495
DOI:
10.1371/journal.pmed.1003495.g001
DOI:
10.1371/journal.pmed.1003495.g002
DOI:
10.1371/journal.pmed.1003495.g003
DOI:
10.1371/journal.pmed.1003495.g004
DOI:
10.1371/journal.pmed.1003495.g005
DOI:
10.1371/journal.pmed.1003495.g006
DOI:
10.1371/journal.pmed.1003495.t001
DOI:
10.1371/journal.pmed.1003495.t002
DOI:
10.1371/journal.pmed.1003495.t003
DOI:
10.1371/journal.pmed.1003495.s001
DOI:
10.1371/journal.pmed.1003495.s002
DOI:
10.1371/journal.pmed.1003495.s003
DOI:
10.1371/journal.pmed.1003495.s004
DOI:
10.1371/journal.pmed.1003495.s005
DOI:
10.1371/journal.pmed.1003495.s006
DOI:
10.1371/journal.pmed.1003495.s007
DOI:
10.1371/journal.pmed.1003495.s008
DOI:
10.1371/journal.pmed.1003495.s009
DOI:
10.1371/journal.pmed.1003495.s010
DOI:
10.1371/journal.pmed.1003495.s011
DOI:
10.1371/journal.pmed.1003495.s012
DOI:
10.1371/journal.pmed.1003495.s013
DOI:
10.1371/journal.pmed.1003495.s014
DOI:
10.1371/journal.pmed.1003495.s015
Sprache:
Englisch
Verlag:
Public Library of Science (PLoS)
Publikationsdatum:
2021
ZDB Id:
2164823-2
Permalink